Abstract Search

ea0063gp17 | Calcium and Bone 1 | ECE2019

Utility of a second technecium99mMIBI-SPECT imaging before re-operating in patients with persistent sporadic primary hyperparathyroidism: results of a retrospective multicentric study

Frey Samuel , Couette Clement , Tresallet Christophe , Hamy Antoine , Caillard Cecile , Blanchard Claire , Lhermite Emilie , Menegaux Fabrice , Drui Delphine , Ansquer Catherine , Mirallie Eric

Introduction: Persistent primary hyperparathyroidism (pHPT) occurs in 2.5 to 15% of cases after parathyroidectomy. Pre-operative localization studies (usually 99mTc-MIBI and cervical ultrasonography (US)) allow focused surgical approach (unilateral neck exploration or minimally invasive parathyroidectomy). Few studies have evaluated the best pre-reoperative approaches in case of persistent sporadic pHPT. The aim of our study is to evaluate the value of a second pre-...

0 shares

ea0098t5 | Trials In Progress | NANETS2023

Phase 3 LEVEL trial of 177Lu-edotreotide vs everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

Capdevila Jaume , Fazio Nicola , Alvarez Rosa , Ansquer Catherine , Baldari Sergio , Baudin Eric , Benavent Marta , Benini Lavinia , Beron Amandine , Berruti Alfredo , Cingarlini Sara , del Olmo-Garcia Maribel , Deshayes Emmanuel , Garcia-Alvarez Alejandro , Garcia-Carbonero Rocio , Haissaguerre Magalie , Hernando Jorge , Anido Herranz Urbano , Jimenez-Fonseca Paula , Lepage Come , Llana Belen , Molina-Cerrillo Javier , Panzuto Francesco , Pubul Virginia , Sansovini Maddalena , Tafuto Salvatore , Taieb David , Teule Alex , Versari Annibale , Villacampa Guillermo , Walter Thomas

Background: Everolimus is the only approved drug for patients with advanced bronchopulmonary neuroendocrine tumors (NET), and there is an urgent unmet need for alternative treatments. Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SST)-positive lung NET. This study aims to investigate the clinical efficacy, safety, and patient-reported outcomes when 177Lu-edotreotide is used to treat...

0 shares

Endocrine Abstracts

Utility of a second technecium99mMIBI-SPECT imaging before re-operating in patients with persistent sporadic primary hyperparathyroidism: results of a retrospective multicentric study

Phase 3 LEVEL trial of 177Lu-edotreotide vs everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (GETNE-T2217)

BiosciAbstracts